{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Midorikawa R"],"funding":["Fujirebio","Astellas Pharma Inc.","National Hospital Organization","Mitsubishi Tanabe Pharma Corporation","Takeda Pharmaceutical Company Limited"],"pagination":["965"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9144302"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(5)"],"pubmed_abstract":["Serological detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N), spike (S), and neutralizing antibodies (Abs) is commonly undertaken to evaluate the efficacy of vaccination. However, the relative efficiency of different SARS-CoV-2 Ab detection systems has not been extensively investigated. Here, we evaluated serological test systems in vaccinated Japanese. SARS-CoV-2 N, S, and neutralizing Abs in sera of 375 healthy subjects a mean 253 days after vaccination were assessed. The sensitivity of Elecsys Anti-SARS-CoV-2 S (Roche S) and Anti-SARS-CoV-2 S IgG (Fujirebio S) was 100% and 98.9%, respectively, with a specificity of 100% for both. The sensitivity of Anti-SARS-CoV-2 neutralizing Ab (MBL Neu) was 2.7%, and the specificity was 100%. Fujirebio S correlated with Roche S (rho = 0.9182, <i>p</i> = 3.97 × 10<sup>-152</sup>). Fujirebio S (rho = 0.1295, <i>p</i> = 0.0121) and Roche S (rho = 0.1232, <i>p</i> = 0.0170) correlated weakly with MBL Neu. However, Roche S did correlate with MBL Neu in patients with COVID-19 (rho = 0.8299, <i>p</i> = 1.01 × 10<sup>-12</sup>) and in healthy subjects more recently after vaccination (mean of 90 days, rho = 0.5306, <i>p</i> = 0.0003). Thus, the Fujirebio S and Roche S results were very similar, but neither correlated with neutralizing antibody titers by MBL Neu at a later time after vaccination."],"journal":["Viruses"],"pubmed_title":["Detection of SARS-CoV-2 Nucleocapsid, Spike, and Neutralizing Antibodies in Vaccinated Japanese."],"pmcid":["PMC9144302"],"funding_grant_id":["NA"],"pubmed_authors":["Midorikawa R","Nagai H","Nakama M","Oka S","Furukawa H","Tohma S","Higuchi T","Nagai N"],"additional_accession":[]},"is_claimable":false,"name":"Detection of SARS-CoV-2 Nucleocapsid, Spike, and Neutralizing Antibodies in Vaccinated Japanese.","description":"Serological detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N), spike (S), and neutralizing antibodies (Abs) is commonly undertaken to evaluate the efficacy of vaccination. However, the relative efficiency of different SARS-CoV-2 Ab detection systems has not been extensively investigated. Here, we evaluated serological test systems in vaccinated Japanese. SARS-CoV-2 N, S, and neutralizing Abs in sera of 375 healthy subjects a mean 253 days after vaccination were assessed. The sensitivity of Elecsys Anti-SARS-CoV-2 S (Roche S) and Anti-SARS-CoV-2 S IgG (Fujirebio S) was 100% and 98.9%, respectively, with a specificity of 100% for both. The sensitivity of Anti-SARS-CoV-2 neutralizing Ab (MBL Neu) was 2.7%, and the specificity was 100%. Fujirebio S correlated with Roche S (rho = 0.9182, <i>p</i> = 3.97 × 10<sup>-152</sup>). Fujirebio S (rho = 0.1295, <i>p</i> = 0.0121) and Roche S (rho = 0.1232, <i>p</i> = 0.0170) correlated weakly with MBL Neu. However, Roche S did correlate with MBL Neu in patients with COVID-19 (rho = 0.8299, <i>p</i> = 1.01 × 10<sup>-12</sup>) and in healthy subjects more recently after vaccination (mean of 90 days, rho = 0.5306, <i>p</i> = 0.0003). Thus, the Fujirebio S and Roche S results were very similar, but neither correlated with neutralizing antibody titers by MBL Neu at a later time after vaccination.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2025-04-18T22:59:09.29Z","creation":"2025-02-19T03:25:15.775Z"},"accession":"S-EPMC9144302","cross_references":{"pubmed":["35632710"],"doi":["10.3390/v14050965"]}}